GSK Stockmann advised G. Pohl-Boskamp GmbH & Co. KG based in Hohenlockstedt in Schleswig-Holstein on the acquisition of Duisburg-based mynoise GmbH. The acquisition allows Pohl-Boskamp to expand its business in the field of digital health applications and protects the future of the Kalmeda® tinnitus app, which was developed by mynoise.
Founded in 2015, mynoise is the developer of the tinnitus app Kalmeda, the first and only fully approved behavioural therapy for chronic tinnitus with class 1 evidence. Since 2022, Kalmeda has been permanently recognised as a “digital health application” (DiGA) by the Federal Institute for Drugs and Medical Devices.
Pohl-Boskamp has been distributing and marketing Kalmeda as a licensed product since 2020. Having acquired mynoise, Pohl-Boskamp can now ensure the continued existence of Kalmeda under its wing. Pohl-Boskamp has plans to develop further digital health applications and hopes the mynoise acquisition will strengthen its business and expertise in this field.
GSK Stockmann provided comprehensive advice to Pohl-Boskamp on the acquisition with a team led by Hamburg M&A partner Max Wilmanns.
Advisers of G. Pohl-Boskamp GmbH & Co. KG
GSK Stockmann: Max Wilmanns (lead, M&A), Dominik Berka (Tax), Martin Hossenfelder (IP/IT); Associates: Christina Lorf (M&A), Sebastian Gerhards (Tax), Jonathan Jung (IP/IT) and Johanna Baumann (M&A).
